Navigation Links
Sangamo BioSciences Reports First Quarter 2012 Financial Results
Date:5/2/2012

gram. Sangamo received an upfront license fee of $13.0 million and is also eligible to receive milestone payments upon the achievement of specified research, regulatory, clinical development, commercialization and sales milestones.  The total amount of such payment, assuming the achievement of all specified milestones, is $213.5 million per gene target, including a total of $8.5 million per target upon the acceptance of an IND or CTA submission.  We are also eligible to receive royalty payments that are a tiered double-digit percentage of net sales of products developed under the collaboration.
  • Initiation of Two New Phase 2 Clinical Trials and Presentation of New Clinical Data From Sangamo's Program to Develop a ZFP Therapeutic as a "Functional Cure" for HIV/AIDS. Sangamo presented new data from its program to develop SB-728-T for HIV/AIDS at the 19th Conference on Retroviruses and Opportunistic Infections (CROI). The data further confirms that SB-728-T meets key requirements for development of a "functional cure" for HIV, by demonstrating durable engraftment, prolonged trafficking and dynamic immunological responsiveness in the gut mucosa.  In addition, the data further validate our strategy for continued development in two ongoing Phase 2 clinical trials (SB-728-1101 and SB-728-902, Cohort 5) that the Company initiated in January 2012. These new clinical studies are designed to maximize the engraftment of CD4+T-cells in which both copies of the CCR5 gene have undergone ZFP Nuclease (ZFN)–mediated modification making them resistant to HIV infection.
  • Publication of Preclinical Study Demonstrating the Use of ZFNs to Engineer Safer and More Potent Cancer Immunotherapies.  The study, published in Nature Medicine, advances the development of novel, cell-based therapies for the treatment of a broad range of cancers.  ZFNs were used to specifically disrupt the native T-cell receptor (TCR) genes i
    '/>"/>

  • SOURCE Sangamo BioSciences, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
    2. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
    3. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
    4. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
    5. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
    6. Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
    7. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
    8. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
    9. Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference
    10. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
    11. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/22/2015)... The laboratory information management systems market is a ... technological advancements due to factors such as rising pressure ... healthcare systems, and increasing government support for adoption of ... players in the market focus on technological advancements to ...
    (Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was ... Pre-Conference seminar on probiotics in San Diego, CA. , ... conference for health care professionals. This year’s pre-conference seminar was ... in health. Dr. Leyer spoke about the emerging topics and ...
    (Date:1/22/2015)... 22, 2015   Cypher Genomics, Inc., the ... SQNM ), the leading molecular diagnostics ... generation noninvasive prenatal tests (NIPT). Through this agreement, ... Mantis™, to advance analysis of clinically-relevant fetal sub-chromosomal ...
    (Date:12/24/2014)... 24, 2014  United Therapeutics Corporation (NASDAQ: UTHR ... MDT ) has submitted a pre-market approval application to ... use of Medtronic,s SynchroMed ® II implantable drug ... with United Therapeutics, Remodulin ® (treprostinil) Injection delivered ...
    Breaking Biology Technology:Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
    ... , PRINCETON, N.J., July ... and protein production company, today announced the appointment of ... Mr. Leone will be responsible for Laureate,s worldwide business ... be supporting the company,s contract development, manufacturing, and bioprocessing ...
    ... , , SAN ... CXM ) and its subsidiary Tissue Repair Company (TRC) ... Phase 2b clinical study and announced plans to provide detailed ... the end of September. The MATRIX trial, a prospective, ...
    ... , , SUNRISE, ... company committed to delivering intelligent devices and biologics that help monitor, ... the US FDA cleared a phase I clinical trial for MyoCell ... The REGEN trial will enroll 15 patients in a multicenter, ...
    Cached Biology Technology:Laureate Pharma Appoints Daniel E. Leone as Vice President of Business Development 2Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications 2Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications 3Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications 4Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications 5United States FDA Clears the REGEN Trial to Test Bioheart's Combination Gene and Stem Cell Therapy in Heart Failure Patients 2United States FDA Clears the REGEN Trial to Test Bioheart's Combination Gene and Stem Cell Therapy in Heart Failure Patients 3United States FDA Clears the REGEN Trial to Test Bioheart's Combination Gene and Stem Cell Therapy in Heart Failure Patients 4
    (Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in ... seeing a staggering demand from its licensees for highly ... revealed, is not solely coming from fitness and health ... "A wearable is only as useful as ...
    (Date:12/10/2014)... Dec. 9, 2014 CIE San Diego has launched an ... tissue that enhances care coordination among social service and care ... a second $1 million grant from the Alliance Healthcare Foundation ... will be recognized as a "Live Well San Diego" partner ...
    (Date:12/10/2014)... SUNNYVALE, California , December 9, 2014 ... with ITN,s BCARD Platform   ... cloud-based enterprise meeting scheduling solutions for business-to-business (B2B) ... the world leader in mobile near-field communication (NFC), ...
    Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
    ... beware. Chances are your male partner is on your ... even when you have kept to the straight and ... constant vigilance, women may be better than men at ... in Richmond and colleagues gave 203 young heterosexual couples ...
    ... human beings "blank slates" that are molded by the cultures ... predispositions genetically based, shaped solely by evolution? The controversy around ... scientific research since Charles Darwin reframed the debate about the ... On Nov. 6, McGill University will host the fourth annual ...
    ... twist on nontraditional uses of ultrasound, a group of ... techniques that can remotely stimulate brain circuit activity. Their ... journal Public Library of Science (PLoS) One , ... for the noninvasive neurostimulation of brain circuits and offers ...
    Cached Biology News:Men are better at detecting infidelities 2What is the origin of ethics? 2Ultrasound shown to exert remote control of brain circuits 2Ultrasound shown to exert remote control of brain circuits 3
    Mouse Axl MAb (Clone 175128)...
    Mouse GDF-8 Propeptide Affinity Purified Polyclonal Ab...
    ... and S.J. Allen (1995) This ... world authorities on current issues relating to ... Several major advances have been made recently ... disease. Topics include molecular neuropathology through clinical ...
    One-step, microplate or cuvet, colorimetric, linear detection range 0.1 mg/dL to 100 mg/dL. Procedure: 20 min....
    Biology Products: